ABIVAX Société Anonyme ABVX
Set alert
At close · Oct 30
After hours · Oct 30, 7:30 PM ET
- YTD
- -35.79%
- 1 year
- -16.97%
- Open
- 87.66
- Prev close
- 89.06
- Mkt cap
- 7.58B
- Vol
- 843.41K
- Avg vol
- 1.10M
- EPS
- -6.08
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 85.81
- High
- 88.90
- Forward P/E
- -22.58
- Beta
- -0.23
- Short ratio
- 5.08
- Inst. own
- 72.26%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 21, 2026
- 50-d avg
- 100.77
- 200-d avg
- 114.29
- 1y target
- 163.58
5D chart
Signals (132)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 4:00 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:45 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:45 PM | 1 day ago |
| SMA: Bearish | Oct 30, 3:40 PM | 1 day ago |
| SMA: Bearish | Oct 30, 3:40 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:20 PM | 1 day ago |
| SMA: Bearish | Oct 30, 3:15 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:10 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:05 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 3:05 PM | 1 day ago |
| RSI: Oversold | Oct 30, 2:45 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:10 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:05 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 12:55 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:45 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:40 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:25 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:20 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:10 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:10 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 12:10 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 11:40 AM | 1 day ago |
| SMA: Bearish | Oct 30, 11:30 AM | 1 day ago |
| SMA: Bearish | Oct 30, 11:25 AM | 1 day ago |
| SMA: Bullish | Oct 30, 11:15 AM | 1 day ago |
| SMA: Bullish | Oct 30, 11:15 AM | 1 day ago |
| SMA: Bearish | Oct 30, 11:10 AM | 1 day ago |
| SMA: Bearish | Oct 30, 11:05 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:45 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 10:35 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:25 AM | 1 day ago |
| RSI: Oversold | Oct 30, 10:05 AM | 1 day ago |
| RSI: Oversold | Oct 30, 9:45 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 9:40 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:30 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:30 AM | 1 day ago |
| SMA: Bullish | Oct 29, 3:55 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:45 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:20 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:50 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 2:45 PM | 2 days ago |
| RSI: Oversold | Oct 29, 2:20 PM | 2 days ago |
| RSI: Oversold | Oct 29, 2:10 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:40 PM | 2 days ago |
| RSI: Oversold | Oct 29, 1:05 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:25 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:25 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:35 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 2 days ago |
| RSI: Overbought | Oct 29, 10:15 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 2 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:55 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:05 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:55 AM | 3 days ago |
| RSI: Overbought | Oct 28, 10:25 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 9:40 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 3 days ago |
| RSI: Oversold | Oct 27, 3:55 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:30 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:20 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:05 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:00 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:25 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:55 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:25 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:20 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:15 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:10 AM | 4 days ago |
| RSI: Overbought | Oct 27, 10:40 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 26, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:45 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:25 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:25 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:15 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:00 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:30 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:05 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 2:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:25 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:05 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:00 PM | 5 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 5 days ago |
News
1 week ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
1 week ago benzinga.com
Wedbush Maintains Neutral on Abivax, Lowers Price Target to $96
Wedbush analyst David Nierengarten maintains Abivax (NASDAQ:ABVX) with a Neutral and lowers the price target from $118 to $96.
2 weeks ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
3 weeks ago seekingalpha.com
Cedar Grove Capital Q3 2026 Portfolio Update
During the quarter, we closed our long positions in MTY Food Group, uniQure, ClearPoint Neuro, and Suja Life Inc. During the quarter, we closed short positions in Bending Spoons SpA, Chipotle Mexican…
-
1 month ago benzinga.com
Abivax To Present Seven Scientific Abstracts On Obefazimod, Lead Drug Candidate For Treatment Of Active Ulcerative Colitis At UEG Week 2026 Meeting
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026Four oral presentations and three posters build upon Phase 3 ABTECT Maintenance and Induction programs in…
1 month ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
1 month ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
1 month ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 month ago seekingalpha.com
Abivax: Priced Right Ahead Of 2 Make-Or-Break Catalysts
Abivax Société Anonyme is advancing obefazimod for ulcerative colitis and Crohn's, with recent safety concerns now largely addressed. ABVX raised $920 million, extending its cash runway into Q4 2029…
1 month ago benzinga.com
These Analysts Slash Their Forecasts On Abivax Following H1 Results
Abivax SA (NASDAQ:ABVX) reported mixed results for the first half of the year on Monday.
1 month ago benzinga.com
These Analysts Slash Their Forecasts On Abivax Following H1 Results
Abivax missed EPS estimates but beat sales in H1; shares dipped. Wedbush and Truist cut price targets to $118 and $151.
-
1 month ago benzinga.com
Truist Securities Maintains Buy on Abivax, Lowers Price Target to $151
Truist Securities analyst Gregory Renza maintains Abivax (NASDAQ:ABVX) with a Buy and lowers the price target from $155 to $151.
-
1 month ago benzinga.com
Wedbush Maintains Neutral on Abivax, Lowers Price Target to $118
Wedbush analyst David Nierengarten maintains Abivax (NASDAQ:ABVX) with a Neutral and lowers the price target from $140 to $118.
-
1 month ago benzinga.com
Abivax H1 EPS $(2.43) Misses $(1.08) Estimate, Sales $2.959M Beat $1.860M Estimate
Abivax (NASDAQ:ABVX) reported quarterly losses of $(2.43) per share which missed the analyst consensus estimate of $(1.08) by 125 percent. This is a 65.31 percent decrease over losses of $(1.47) per…
1 month ago globenewswire.com
Abivax Presents Business Updates and First Half 2026 Financial Results
Abivax Presents Business Updates and First Half 2026 Financial Results Chris Rabbat to succeed Fabio Cataldi as Chief Medical Officer; Tim Kelly appointed Chief Technical Officer to advance…
1 month ago benzinga.com
Earnings Scheduled For September 21, 2026
Companies Reporting Before The Bell • Ennis (NYSE:EBF) is expected to report earnings for its second quarter. Companies Reporting After The Bell • Abivax (NASDAQ:ABVX) is projected to report…
1 month ago benzinga.com
Nasdaq Gains Over 100 Points, Posts Weekly Gain: Investor Sentiment Improves Slightly, But Greed Index Remains in ‘Fear’ Zone
Market sentiment improved slightly but stayed in Fear; stocks were mixed, the Dow had its worst week since March.
1 month ago defenseworld.net
Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Rating of “Moderate Buy” by Brokerages
Abivax SA Sponsored ADR (NASDAQ: ABVX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the sixteen research firms that are currently covering the company, MarketBeat.com…
1 month ago benzinga.com
Accenture, Abivax and 3 Stocks to Watch Heading Into Monday
With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
1 month ago benzinga.com
Accenture, Abivax and 3 Stocks to Watch Heading Into Monday
Stocks in focus: Abivax, Marygold and Neuphoria report losses; Accenture partners with Anthropic, while Lobo Technologies posts H1 growth.
1 month ago zacks.com
4 Biotech Stocks to Watch as Potential Takeover Targets
Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.
-
1 month ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 month ago benzinga.com
Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
ABIVAX Société Anonyme (NASDAQ:ABVX) will release its first-half earnings report after the closing bell on Monday, Sept. 21.
1 month ago benzinga.com
Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Abivax will report H1 earnings Sept. 21; analysts expect a $1.08 loss/share and $1.86M revenue.
1 month ago benzinga.com
This Amer Sports Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiate: Buy—Abivax ($155), Amer Sports ($42) and more
-
1 month ago benzinga.com
Goldman Sachs Initiates Coverage On Abivax with Buy Rating, Announces Price Target of $155
Goldman Sachs analyst Rajan Sharma initiates coverage on Abivax (NASDAQ:ABVX) with a Buy rating and announces Price Target of $155.
1 month ago zacks.com
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why
Abivax SA Sponsored ADR (ABVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
-
2 months ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
2 months ago defenseworld.net
Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Recommendation of “Moderate Buy” by Brokerages
Shares of Abivax SA Sponsored ADR (NASDAQ: ABVX - Get Free Report) have received an average rating of "Moderate Buy" from the fifteen brokerages that are presently covering the stock, Marketbeat…
-
2 months ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
2 months ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
3 months ago benzinga.com
Abivax Completes Pre-New Drug Application Interaction For Obefazimod With FDA To Treat Adults With Moderately To Severely Active Ulcerative Colitis
Abivax SA (Euronext PARIS:FR0012333284 – ABVX / Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural
-
3 months ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
3 months ago seekingalpha.com
Abivax: Obefazimod Goes The Distance And So Does My Buy Rating
Abivax (ABVX) maintains a Buy rating, supported by robust Phase 3 maintenance data for obefazimod in ulcerative colitis. ABVX demonstrated clinical remission rates of 50.8%–51.3% at week 44, with…
3 months ago zacks.com
Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?
After reaching an important support level, Abivax SA Sponsored ADR (ABVX) could be a good stock pick from a technical perspective. ABVX recently experienced a "golden cross" event, which saw its…
3 months ago cnbc.com
Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
Abivax's latest funding round allows the biotech to move toward a U.S. launch of its bowel disease drug without backing from Big Pharma, its CEO told CNBC on Friday. The French biotech has been under…
-
3 months ago benzinga.com
9 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
3 months ago benzinga.com
Piper Sandler Maintains Overweight on Abivax, Raises Price Target to $175
Piper Sandler analyst Allison Bratzel maintains Abivax (NASDAQ:ABVX) with a Overweight and raises the price target from $165 to $175.
3 months ago fool.com
3 Soaring Stocks That May Have More Upside Ahead
The sky is the limit for these companies.
3 months ago marketbeat.com
Abivax: Wall Street Catches Up to the Data
Shares of Abivax NASDAQ: ABVX were up more than 40% in the month ending July 6, after the company announced positive results from its late-stage (Phase 3) trial of its lead candidate, Obefazimod,…
3 months ago globenewswire.com
Abivax Announces Closing of $920 Million Public Offering
Abivax Announces Closing of $920 Million Public Offering PARIS, France, July 6, 2026 –10:05 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a…
-
4 months ago benzinga.com
Truist Securities Maintains Buy on Abivax, Raises Price Target to $155
Truist Securities analyst Gregory Renza maintains Abivax (NASDAQ:ABVX) with a Buy and raises the price target from $135 to $155.
4 months ago benzinga.com
Why SurgePays Shares Are Trading Higher By 59%; Here Are 20 Stocks Moving Premarket
Surgepays Inc (NASDAQ: SURG) rose in pre-market trading after amending agreement with wireless network provider, shares jumped 59% to $0.66.
4 months ago wsj.com
Abivax Shares Continue Climbing After Biotech Firm Moves to Bolster Balance Sheet
Shares rose 5% after the biotech moved to bolster its balance sheet through an upsized stock offering, signaling investor appetite in the wake of positive clinical-trial data.
4 months ago globenewswire.com
Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
4 months ago reuters.com
Abivax nears $11 billion valuation after fundraising eases M&A pressure
Abivax SA raised $800 million in an expanded share sale on Wednesday after strong investor demand, valuing the French biotechnology company at nearly $11 billion and easing pressure to pursue a…
-
4 months ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
4 months ago benzinga.com
Citizens Reiterates Market Outperform on Abivax, Maintains $187 Price Target
Citizens analyst Jason N. Butler reiterates Abivax (NASDAQ:ABVX) with a Market Outperform and maintains $187 price target.
4 months ago globenewswire.com
Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
-
4 months ago benzinga.com
Abivax Announces Pricing Of Underwritten Public Offering Of 6.40M ADSs At $125.00 Each
Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary SharesUpsized offering increased from the previously announced $600M to $800M at $125.00…